期刊
CURRENT TREATMENT OPTIONS IN ONCOLOGY
卷 21, 期 4, 页码 -出版社
SPRINGER
DOI: 10.1007/s11864-020-0711-9
关键词
Peptide receptor radionuclide therapy (PRRT); Somatostatin analogues (SSAs); Somatostatin receptors (SSTRs); Toxicity; Myelodysplastic syndrome (MDS; Salvage therapy
类别
Opinion statement Neuroendocrine tumors (NETs) are a heterogenous group of neoplasms characterized by varied biological hallmarks and behavior, ranging from indolent to aggressive. For many decades, somatostatin analogues and few targeted therapies were available for NETs and these therapies had minimal response rates. However, there have been a number of recent treatment advances. Peptide receptor radionuclide therapy (PRRT) is a novel approach to treatment of NETs and has changed the landscape of treatment for NETs. It is a form of targeted therapy in which a radiolabeled somatostatin analogue delivers radiation specifically to tumor cells expressing the somatostatin receptor.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据